Alkermes (ALKS) Receivables (2011 - 2026)
Alkermes' (ALKS) quarterly Receivables came in at $456.5 million in Q2 2026, up 28.11% year-over-year from $356.3 million in Q2 2025, and up 11.98% quarter-over-quarter from $407.6 million in Q1 2026.
Analysis
Alkermes (ALKS) Receivables (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Receivables for 16 consecutive years, with $456.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Receivables rose 28.11% year-over-year to $456.5 million in Q2 2026; TTM through Jun 2026 was $456.5 million, a 28.11% increase from a year earlier, with the FY2025 full-year figure at $399.8 million, down 11.94% from the prior year.
- Receivables was $456.5 million for Q2 2026 at Alkermes, up from $407.6 million in the prior quarter.
- Over five years, Receivables peaked at $456.5 million in Q2 2026 and troughed at $1.4 million in Q4 2023.
- A 5-year average of $302.8 million and a median of $334.3 million in 2023 frame the typical range for Receivables.
- Across the five-year window, Receivables slumped 92.09% in 2023 and jumped 27486.26% in 2024, its largest moves.
- Over 5 years, Receivables stood at $17.9 million in 2022, then tumbled by 92.09% to $1.4 million in 2023, then jumped by 27486.26% to $389.5 million in 2024, then fell by 14.25% to $334.0 million in 2025, then jumped by 36.66% to $456.5 million in 2026.
- The last three Receivables figures came in at $456.5 million (Q2 2026), $407.6 million (Q1 2026), and $334.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | 12.49 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 10.13 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 1.13 Bn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | 310.30 Mn |
| 10 | Alkermes | 7.56 Bn | 6.90 Bn | 397.90 Mn | 456.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 456.48 Mn |
| Mar 31, 2026 | 407.63 Mn |
| Dec 31, 2025 | 334.03 Mn |
| Sep 30, 2025 | 355.11 Mn |
| Jun 30, 2025 | 356.33 Mn |
| Mar 31, 2025 | 321.75 Mn |
| Dec 31, 2024 | 389.52 Mn |
| Sep 30, 2024 | 370.18 Mn |
| Jun 30, 2024 | 369.91 Mn |
| Mar 31, 2024 | 317.08 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 340.46 Mn |
| Jun 30, 2023 | 334.48 Mn |
| Mar 31, 2023 | 277.61 Mn |
| Dec 31, 2022 | 17.86 Mn |
| Sep 30, 2022 | 267.28 Mn |
| Jun 30, 2022 | 262.33 Mn |
| Mar 31, 2022 | 270.15 Mn |
| Dec 31, 2021 | 26.73 Mn |
| Sep 30, 2021 | 292.67 Mn |